188440-21-3Relevant articles and documents
Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists
Amaudrut, Jér?me,Argiriadi, Maria A.,Barth, Martine,Breinlinger, Eric C.,Bressac, Didier,Broqua, Pierre,Calderwood, David J.,Chatar, Mohamed,Cusack, Kevin P.,Gauld, Stephen B.,Jacquet, Sébastien,Kamath, Rajesh V.,Kort, Michael E.,Lepais, Valérie,Luccarini, Jean-Michel,Masson, Philippe,Montalbetti, Christian,Mounier, Laurent,Potin, Dominique,Poupardin, Olivia,Rouaud, Sylvie,Spitzer, Luc,Wallace, Craig D.
, p. 1799 - 1806 (2019/05/17)
A high-throughput screen against Inventiva's compound library using a Gal4/RORγ-LBD luciferase reporter gene assay led to the discovery of a new series of quinoline sulphonamides as RORγ inhibitors, eventually giving rise to a lead compound having an inte
NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM
-
Page/Page column 9-10, (2010/11/08)
Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group.
Benzenesulfonamide derivatives as bradykinin antagonists
-
, (2008/06/13)
PCT No. PCT/FR96/01262 Sec. 371 Date Apr. 7, 1997 Sec. 102(e) Date Apr. 7, 1997 PCT Filed Aug. 7, 1996 PCT Pub. No. WO97/07115 PCT Pub. Date Feb. 27, 1997The present invention relates to compounds selected from the group consisting of the compounds of formula (I): X is a halogen atom, A is -CH2-, -CH(OH)-, -CH(NH-COCH3)- or S, R is H, CO2H, CO2-B-R1 or CO-N(R2)-B-R1, B is linear, branched or cyclic C1-C10-alkylene, R1 is H, CH2OH, CH2-O-CH3, CH2-NR3R4 or phenyl, R2 is H or C1-C4-alkyl, R3 is H or linear, branched or cyclic C1-C10-alkyl, R4 is H or linear or branched C1-C10-alkyl, it being possible for NR3R4 to be a saturated heterocyclic radical having from 5 to 8 ring members and containing at least one nitrogen atom, and the carbon carrying the substituent R, when Q is saturated, can be of indeterminate (R,S) configuration or of determinate (R) or (S) configuration; and their addition salts. It further relates to their use in therapeutics, especially for pathological conditions involving bradykinin.